Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. by Bossuyt, Xavier et al.
Anti-neutrophil cytoplasmic antibodies (ANCAs), such 
as those directed towards proteinase 3 (PR3) and myelo-
peroxidase (MPO), are associated with a distinct form of 
small-vessel vasculitis, known as ANCA-associated vas-
culitis (AAV), a term that encompases granulomatosis 
with polyangiitis (GPA) and microscopic poly angiitis 
(MPA). Screening for the presence of ANCAs is a com-
monly used diagnostic test for AAV. According to an 
international consensus statement issued in 1999 (REF. 1), 
indirect immunofluorescence (IIF) should be used as 
the initial screening method to detect the presence of 
ANCAs. Samples that test positive by IIF should then be 
tested by immunoassays to detect ANCAs specific for 
PR3 and MPO. Although this testing algorithm is still 
widely applied, the position of IIF is being questioned.
Over the past 15 years, the performance of enzyme-
linked immunosorbent assays (ELISAs) have improved 
and novel, sensitive and automated technologies, such 
as fluoroenzyme immunoassays, chemiluminescence 
assays and multiplexed flow immunoassays, have been 
introduced. Additionally, assay setup (antigen pres-
entation) has advanced with the development of sec-
ond generation (capture-based) and third generation 
(anchor-based) assays. In general, currently available 
assays for PR3-ANCAs and MPO-ANCAs are highly 
sensitive and specific for diagnosing GPA and MPA 
(reviewed elsewhere2).
The availability of reliable antigen-specific immuno-
assays has raised doubts as to whether the two-stage 
diagnostic strategy currently recommended for ANCA 
detection is the best approach2,3. The use of antigen- 
specific assays as the initial and/or only step has been 
suggested as an alternative approach to screening by 
IIF (REFS 4,5). In a 2016 large multicentre study by the 
European Vasculitis Study Group (EUVAS), the diag-
nostic performance of antigen-specific immunoassays 
was confirmed to equal or even to exceed the diagnostic 
performance of IIF (REF. 6).
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Abstract | Anti-neutrophil cytoplasmic antibodies (ANCAs) are valuable laboratory markers used 
for the diagnosis of well-defined types of small-vessel vasculitis, including granulomatosis with 
polyangiitis (GPA) and microscopic polyangiitis (MPA). According to the 1999 international 
consensus on ANCA testing, indirect immunofluorescence (IIF) should be used to screen for 
ANCAs, and samples containing ANCAs should then be tested by immunoassays for proteinase 3 
(PR3)-ANCAs and myeloperoxidase (MPO)-ANCAs. The distinction between PR3-ANCAs and 
MPO-ANCAs has important clinical and pathogenic implications. As dependable immunoassays 
for PR3-ANCAs and MPO-ANCAs have become broadly available, there is increasing 
international agreement that high-quality immunoassays are the preferred screening method for 
the diagnosis of ANCA-associated vasculitis. The present Consensus Statement proposes that 
high-quality immunoassays can be used as the primary screening method for patients suspected 
of having the ANCA-associated vaculitides GPA and MPA without the categorical need for IIF, and 
presents and discusses evidence to support this recommendation.
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Given the improvements in antigen-specific 
immuno assays, the international consensus on the test-
ing of ANCAs in small-vessel vasculitis seems in need 
of updating7–10. In this manuscript, a revised 2017 inter-
national consensus is proposed by a group of international 
experts (from North and Central America, Australia, 
Europe and Asia) in the ANCA field. This Consensus 
Statement highlights the value of ANCA testing as a tool 
for diagnosis (but not follow-up) of GPA and MPA and 
gives a historical perspective of ANCAs in small-vessel 
vasculitis. This Consensus Statement does not, however, 
present evidence-based guidelines or a meta-analysis.
Methods
This Consensus Statement was prepared by a group 
of experts from four European laboratories (X.B., J.D., 
N.R., J.W.C.T. and E.C.) in person and by correspond-
ence. The draft was circulated to each contributor and 
modified, and the resulting document was distributed by 
e-mail to 16 experts from four continents, selected based 
on their expertise and knowledge in clinical and/or lab-
oratory aspects of AAV. This revised document resulted 
in a second round of discussions and revisions. The final 
document was returned to all contributors for ratification.
The Consensus Statement is based on the results of a 
multicentre European Vasculitis Study Group (EUVAS) 
evaluation of the value of IIF versus antigen-specific 
immunoassays for ANCA detection6,11,12. This study, 
which showed a large variability between different 
IIF methods and a good diagnostic performance of 
PR3-ANCA and MPO-ANCA immunoassays6, indicated 
that the 1999 international consensus on ANCA testing 
for AAV needed revision. When the consensus was put 
together, the topics that were discussed encompassed IIF 
versus immunoassays for ANCA detection in GPA and 
MPA, diagnostic strategies, clinical indications for ANCA 
testing, value-added reporting of ANCA test results and 
ANCAs in conditions other than GPA and MPA.
Historical perspective
First discoveries in ANCA detection. The history of 
ANCAs in AAV is depicted in FIG. 1 and has been pre-
viously described elsewhere13,14. Although ANCAs were 
initially discovered in 1959 in patients with chronic 
inflammatory disorders15, the association between vascu-
litis (in particular glomerulonephritis) and autoantibodies 
reacting with cytoplasmic components of neutrophils only 
became apparent in 1982 (REF. 16). In 1985, van der Woude 
et al. detected such anti-cytoplasmic antibodies by IIF in a 
mixed Dutch–Danish cohort of patients with GPA17, not-
ing that these antibodies produced a cytoplasmic staining 
pattern (C-ANCA). Following description of C-ANCA, 
autoantibodies that produce a perinuclear staining pat-
tern (P-ANCA) by IIF were also reported in patients with 
systemic arteritis and glomerulonephritis18,19; the relevant 
autoantigens for C-ANCA and P-ANCA were identified 
as PR3 and MPO, respectively18,20,21,22. ANCAs have sub-
sequently been associated with other small-vessel vascu-
litides, including MPA, eosinophilic granulomatosis with 
polyangiitis (EGPA) and idiopathic necrotizing crescentic 
glomerulonephritis 2,3,13,14.
At first, ‘in-house’ ELISAs were used for the detection 
of MPO-ANCAs and PR3-ANCAs. However, following a 
recognized need for standardization, international efforts 
were undertaken to develop and standardize solid- phase 
ANCA assays23,24 (discussed below). In 1998, 15 clin-
ical centres evaluated such standardized assays for the 
detection of ANCA in patients with idiopathic systemic 
vasculitis25 (TABLE 1), concluding that the diagnostic value 
of ANCA detection by IIF could be greatly enhanced by 
combining this test with an antigen-specific ELISA. In 
this study, Hagen et al. showed that ANCA detection 
by IIF was sensitive for GPA, MPA and renal-limited 
vasculitis (sensitivities of 81–85%) but had a low spec-
ificity (76%). Combining IIF with an ELISA (PR3-ANCA 
and MPO-ANCA) increased the specificity to 98% and 
decreased the sensitivities to 67–82%25. The results of this 
multicentre study were the basis of the 1999 interna-
tional consensus statement on the testing and reporting 
of ANCAs1. This 1999 consensus statement states that 
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ANCAs are best demonstrated by using a combination 
of IIF and immunoassay (PR3-ANCA or MPO-ANCA) 
and that IIF must be performed on all serum samples 
of patients suspected of having AAV1. Serum samples 
containing ANCAs by IIF should then be tested for 
PR3-ANCAs and MPO-ANCAs1. The testing algorithm 
proposed by this consensus was validated in 2002 in a 
meta-analysis study, leading to the conclusion that com-
bining results obtained by IIF and ELISA (combining 
either C-ANCA and PR3-ANCA or P-ANCA and MPO-
ANCA findings) optimizes the diagnostic performance 
of ANCA testing for AAV26.
Incorporation of ANCA tests in clinical decisions. In 
the early 1990s, classification criteria and nomenclature 
for the small-vessel vasculitides were assigned by the 
American College of Rheumatology27,28 and the Chapel 
Hill Consensus Conference (CHCC), respectively29. 
These criteria were based on clinical manifestations and 
hallmark pathological features of tissue biopsy samples, 
but did not incorporate ANCA testing. Small-vessel vas-
culitides were originally considered to be only ANCA-
associated, but subsequent animal model studies showed 
that ANCAs also have pathogenic potential30,31, which 
was clearly demonstrated for MPO-ANCAs in 2002 
(REF. 32), and later indirectly for PR3-ANCAs33. The fact 
that different approaches were needed to demonstrate the 
pathogenic potential of MPO-ANCAs and PR3-ANCAs 
in these studies increased the awareness that instead of 
distinguishing between patients with GPA, MPA and 
EGPA, differentiating between patients with MPO-
ANCAs or PR3-ANCAs might be more clinically rel-
evant34–37. This notion was underscored in 2012 by the 
finding that these autoantibodies can be used to differ-
entiate between genetically distinct subsets of patients 
with AAV38. The combined potential pathogenic role of 
these auto antibodies32,33 and the good test performances 
of the ANCA-assays26, formed the basis for incorporating 
ANCAs into nomenclature criteria; in the 2012 CHCC 
update on the nomenclature of the vasculitides, AAV was 
included as a category of vasculitis39. Importantly, CHCC 
is a nomenclature system, not a classification system or 
a diagnostic system, and at present there are no vali-
dated diagnostic criteria for AAV. ANCA detection was 
included as part of a consensus methodology developed in 
2007 for the classification of AAV and polyarteritis nodosa 
in epidemiological studies40, and EULAR have pointed to 
considering ANCA in diagnostic and classification criteria 
for systemic vasculitis41.
Novel technical developments in ANCA detection. 
Since the description of the first commercial ANCA 
ELISA in 1990 (REF. 42), an increasing number of com-
mercial ANCA assays have become available. ELISAs 
have evolved in the way in which antigens are cou-
pled to the carrier: from direct antigen binding (first 
generation ELISA) to capture-based antigen binding 
(second generation ELISA) and anchor-based antigen 
binding (third generation ELISA)2,3,43–48. Similarly, IIF 
has also undergone technical innovations: neutrophil 
substrates have been combined with antigen-specific 
Figure 1 | Historical landmarks of ANCA-testing in small vessel vasculitis. In the 
past 25 years, substantial progress has been made in the development of assays for 
detecting anti-neutrophil cytoplasmic antibodies (ANCAs). Achievements have been 
made in antigen characterization (indicated in green), in the standardization of ANCA 
assays (indicated in blue), in incorporation of ANCAs in nomenclature and 
classification proposals (indicated in pink) and in ANCA technology (indicated in grey). 
Consensus statements on ANCA testing are indicated in orange. In this timeline,  
the dates for the distinct assays formats concern the publications of commercially 
available immunoassays. CHCC, Chapel Hill Consensus Conference; C-ANCA, 
cytoplasmic ANCA staining pattern; ELISA, enzyme-linked immunosorbent assay;  
GPA, granulomatosis with polyangiitis; IIF, indirect immunofluorescence; MPO, 
myeloperoxidase; PR3, proteinase 3; P-ANCA, perinuclear ANCA staining pattern. 
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biochip and microbead technology49,50, and automatic 
pattern recognition devices have become available to 
support the evaluation of IIF (REFS 51,52). However, inno-
vations in ANCA detection have not only been limited 
to IIF and ELISAs; alternative solid-phase assays are also 
now being marketed, including dot and line immuno-
assays53, fluorescent-enzyme immunoassays (FEIA)54,55, 
addressable- laser-bead immunoassays (ALBIA)56,57,58,59 
and chemiluminescent immunoassays (CLIA)60,61. Many 
of these assays are reliable methods for ANCA detection, 
and such advances have challenged the role of IIF in 
ANCA testing and in the testing algorithm recommended 
by the 1999 international consensus6.
Harmonization and standardization of ANCA testing. 
A standard procedure for ANCA IIF was released in 
1988 (REF. 62), prescribing the use of a mixture of neu-
trophils and other white blood cells smeared on glass 
slides and fixed with ethanol to differentiate between 
C-ANCA and P-ANCA, and to determine the ANCA 
titre of a sample. The result is considered ‘not determina-
ble’ if the serum contains antinuclear antibodies (ANAs), 
as detected on human epithelial type 2 (HEp-2) cells, at a 
similar titre to that determined for P-ANCA. At present, 
most clinical laboratories use commercial cell substrates 
for ANCA detection by IIF and, in many cases, neutro-
phils are used on their own rather than in a mixture with 
other cells.
Efforts in harmonizing ANCA detection began in 
1993 with an international study on the standardization of 
ANCA assays23. In this multicentre study, the value 
of IIF and solid-phase techniques (ELISAs) for ANCA 
detection was evaluated23. The IIF test results across 
different centres were comparable for sera containing 
high ANCA titres (even when different methods were 
used), whereas the results indicated that the ELISAs for 
PR3-ANCAs were not well-standardized, except when 
purified PR3 was used as the antigen preparation23. For 
the MPO ELISAs, various antigen preparations revealed 
only minor discrepancies in results, with the researchers 
concluding that all of these MPO preparations could be 
used in ELISAs for the detection of MPO-ANCAs23.
An addendum to the 1999 international consensus was 
released in 2003 recommending the use of internal and 
external quality control procedures in ANCA testing63. 
In 2007, the first human reference sera for MPO-ANCAs 
and PR3-ANCAs became available via the Centers for 
Disease Control and Prevention (CDC). These samples 
were prepared under the auspices of the International 
Union of Immunological Societies (IUIS). Each refer-
ence preparation was obtained by plasmapheresis from 
a single donor and was confirmed to be monospecific 
for either MPO or PR3. To our knowledge, at least four 
companies currently calibrate their ANCA assays against 
the IUIS-CDC reference sera: the second generation 
ANCA ELISAs of Wieslab (Euro-Diagnostica), a third 
generation ANCA FEIA (Thermo-Fisher), a cytobead 
IIF assay (Medipan) and a CLIA (Inova). In 2016, the 
Institute for Reference Materials and Measurements 
(IRMM) released certified reference material for MPO-
ANCAs (ERM-DA476/IFCC)64. This reference material 
is based on a plasmapheresis sample from a single patient 
with vasculitis. A similar approach for developing cer-
tified reference material for PR3-ANCAs is currently 
in progress64. Although the use of a certified reference 
material will reduce variability between ANCA results 
obtained with different assays, it should be noted that 
auto antibodies are not a uniform analyte. This caveat 
holds true for patient sera, as well as for the reference anti-
body preparations. Antibodies differ in terms of their IgG 
subclass composition as well as the avidity, glycosylation 
and epitope specificity of the antibodies65–74. In particular, 
epitope specificity might affect standardization of different 
assay formats, as the accessibility of epitopes might differ 
between different assay formats. Therefore, the feasibility 
of using reference antibody preparations for standardi-
zation of autoantibody assays (that is, MPO-ANCA and 
PR3-ANCA assays) remains to be established12.
Table 1 | Comparison of the specificity and sensitivity for different ANCA assays
Study population IIF Immunoassay
C-ANCA P-ANCA PR3-ANCA MPO-ANCA
Specificity in disease controls
Hagen et al. (n = 184) 95% 81% 86–89% 91%
Damoiseaux et al. (n = 924) 97–98% 81–96% 98–99% 96–99%
Sensitivity in ‘newly diagnosed’ GPA
Hagen et al. (n = 97) 64% 21% 65–67% 24%
Damoiseaux et al. (n = 186) 65–77% 11–15% 77–81% 9–12%
Sensitivity in ‘newly diagnosed’ MPA
Hagen et al. (n = 44) 23% 58% 25–27% 58%
Damoiseaux et al. (n = 65) 5–6% 85–89% 5–9% 71–88%
This table compares the specificity and sensitivity of indirect immunofluorescence (IIF) and antigen-specific immunoassays for 
newly diagnosed patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) as reported by Hagen 
et al. (the basis for the 1999 consensus)25 and Damoiseaux et al. (the basis for the revised 2017 consensus)6. Hagen et al.25 used one 
IIF method, three different proteinase 3 (PR3)-anti-neutrophil cytoplasmic antibody (ANCA) enzyme-linked immunosorbent assays 
(ELISAs) and one myeloperoxidase (MPO)-ANCA ELISA, whereas Damoiseaux et al.6 performed IIF using two methods at two 
different sites and eight different PR3-ANCA and eight different MPO-ANCA antigen-specific enzyme immunoassays. AAV, 
ANCA-associated vasculitis. C-ANCA, cytoplasmic ANCA staining pattern; P-ANCA, perinuclear ANCA staining pattern.
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Pre-test probability
Probability of an individual 
having a disease without prior 
knowledge of the results of 
laboratory tests.
Rationale for a new consensus
In a 2016 multicentre EUVAS evaluation, the perfor-
mance of manual and automated IIF was compared 
with the performance of various antigen-specific 
immunoassays for ANCA detection6,11. Four European 
centres contributed samples and clinical data from 
newly diagnosed patients with GPA (n = 186) and 
MPA (n = 65) and relevant disease controls (n = 924)6,11. 
Because ANCA levels might change during treatment, 
only newly diagnosed patients were included. Eight 
different antigen-specific immunoassays (from seven 
manufacturers, encompassing different technological 
platforms) and four different IIF assays (including two 
automated assays) were evaluated6,11. As illustrated in 
FIG. 2, the results of the study revealed a large amount of 
variability between IIF methods. Moreover, the pattern 
assignment between IIF methods also varied11. By con-
trast, immuno assays for PR3-ANCAs and MPO-ANCAs 
had a high diagnostic performance6. This study, which 
was performed on diagnostic samples obtained from 
patients who had not received any immunosuppressive 
treatment, did not reveal consistent differences between 
different assay generations and formats. Hence, in con-
trast to expectations, the improvements in test character-
istics were independent of the assay principle. Notably, 
some patients tested negatively by both IIF and immuno-
assay, or by either immunoassay or IIF. Depending on 
the assay, 11−17% of patients with AAV were negative 
by IIF and 9−16% by immunoassay6. Hence, antigen- 
specific immunoassays might detect antibodies that are 
missed by IIF and vice versa6.
When compared with the assays used by Hagen et al.25, 
the antigen-specific immunoassays used in the EUVAS 
study performed much better, with a higher specific-
ity, demonstrating the marked improvements that have 
been made to these assays (TABLE 1). Of note, however, 
the composition of the control groups differed between 
the two studies. For example, Hagen et al.25 included 
patients with inflammatory bowel disease (IBD), 
whereas Damoiseaux et al. did not6, using instead rel-
evant disease controls for AAV (that is, patients for 
whom the clinician considered the possibility of AAV 
and requested ANCA testing, but for whom AAV was 
eventually excluded), as well as cohorts of patients with 
a systemic rheumatic disease.
Given the large variability between IIF methods and 
poor performance of some IIF methods (manual as well 
as automated), in addition to the good performance of 
the immunoassays evaluated, the authors of the EUVAS 
study concluded that screening with IIF and follow-up 
testing with antigen-specific immunoassay was not nec-
essary for maximal diagnostic accuracy6. These results 
indicated that the 1999 international consensus on 
ANCA testing for AAV needed revision7–10.
New recommendations
In this Consensus Statement, we recommend the use 
of high-quality immunoassays as the preferred first 
screening method for GPA and MPA, and put forward 
a new testing algorithm (recommendations 1–6). These 
recommendations are visually represented in FIG. 3 and 
displayed in BOX 1.
To determine if ANCA testing is advisable, adherence 
to a strict gating strategy, based on clinical manifesta-
tions defined in the 1999 consensus1 (BOX 2), is recom-
mended. This strategy strongly reduces the number of 
ANCA test requests and improves the diagnostic perfor-
mance of ANCA testing, with fewer false positive results 
(recommendation 1)75–77.
Based on the results of this consensus initiative, 
there is substantial international agreement that high- 
quality antigen-specific immunoassays are the preferred 
screening methodology for the diagnosis of AAV (rec-
ommendation 2). IIF is no longer deemed suitable as the 
first screening test, and adds little additional benefit to 
antigen- specific assays in the diagnosis of AAV when the 
pre-test probability for the disease is high6.
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Figure 2 | Comparison of the receiver operating 
characteristics curves for different ANCA assays. This 
graph depicts the receiver operating characteristics (ROC) 
curves for different methods of anti-neutrophil cytoplasmic 
antibody (ANCA) detection by indirect 
immunofluorescence (IIF) and by myeloperoxidase 
(MPO)-specific and proteinase 3 (PR3)-specific 
immunoassays. The figure demonstrates the substantial 
variation between the IIF methods and the good 
performance of antigen-specific immunoassays. IIF was 
performed with ethanol-fixed neutrophils using either the 
manual Copenhagen approach (blue line) or automated 
Aklides platform (orange line). IIF was also performed with 
ethanol-fixed neutrophils in combination with additional 
tests on formalin-fixed neutrophils and HEp-2 cells using 
either the manual Bad Bramstedt approach (red line) or 
automated EuroPattern platform (purple line). 
Immunoassays were performed using a third generation 
PR3-ANCA and first generation MPO-ANCA enzyme-linked 
immunosorbent assays (ELISAs) from Euroimmun (green 
line). This figure was adapted with permission obtained 
from Csernok, E., et al. Evaluation of automated 
multi-parametric indirect immunofluorescence assays to 
detect anti-neutrophil cytoplasmic antibodies (ANCA) in 
granulomatosis with polyangiitis (GPA) and microscopic 
polyangiitis (MPA). Autoimmun. Rev. 15, 736–741 (2016). 
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Likelihood ratios
The probability of a specific 
result occuring in a group of 
patients divided by the 
probability of the same result 
occuring in a group of controls.
Post-test probability
Probability of an individual 
having a disease with prior 
knowledge of the results of 
laboratory tests.
Single immunoassays never have a sensitivity and 
specificity of 100%. In patients where there is a high 
degree of clinical suspicion and negative ANCA test 
results, testing by another method can be useful to 
increase sensitivity (recommendation 3). False-positive 
results do occur with immunoassays, mainly in samples 
with a low degree of positivity78. Therefore, performing 
a second assay or IIF can marginally increase the spec-
ificity in cases of low-positive test results10. When new 
assays are introduced (including assays not included in 
the EUVAS study6), the diagnostic performance of such 
assays should be checked based on samples from patients 
with GPA or MPA and relevant disease controls.
A diagnosis of AAV cannot be excluded for ANCA-
negative patients (recommendation 4) and biopsies of 
the affected organs should be performed in seronegative 
patients6. Although ANCAs are helpful in the diagnosis 
of AAV, the diagnosis of AAV should be based on clinico-
pathological features (recommendation 5).
Interpretation of test results can be improved by the 
application of appropriately designed reference ranges 
(and test result intervals) for antibody levels (rec-
ommendation 6). The concept of test result interval- 
specific likelihood ratios is explained in the next section.
The specific role of IIF testing in ANCA testing algo-
rithms should be determined individually by diagnostic 
laboratories on the basis of the specific clinical need and 
circumstances of the laboratory. If a laboratory prefers 
to use IIF as a screening assay in locally determined 
best-testing algorithms, then the laboratory needs to 
ensure that the IIF operates at a high level of sensitivity, as 
the performance of IIF varies greatly between laboratories.
Improving clinical interpretations
As immunoassays are expected to be increasingly used to 
screen for AAV, retrieving the maximum amount of clin-
ically useful information from PR3-ANCA and MPO-
ANCA test results is important. Traditionally, a single 
cut-off value is employed to predict clinically- relevant 
reactivity. However, a lot of information is lost when 
only binary results (positive or negative) are considered, 
whereas the likelihood for AAV increases with increasing 
levels of PR3-ANCAs and MPO-ANCAs79.
The likelihood ratio helps to describe the clinical 
value of a test result. This ratio can be defined for differ-
ent test result intervals of an assay and is independent of 
the disease prevalence and pre-test probability. A like-
lihood ratio of 1 indicates no difference in pre-test to 
post-test probability, whereas likelihood ratios of >10 or 
<0.1 indicate large, often clinically important differences 
in pre-test to post-test probability79,80,81.
A detailed analysis of the large dataset from the multi-
national EUVAS study6 exemplified and confirmed that 
the likelihood ratio for AAV increases with increasing 
levels of PR3-ANCAs and MPO-ANCAs for all immuno-
assays included in the study78. For example, the likelihood 
ratio for AAV was calculated to be 0.1, 1.2, 10.2, 64.6, 
and ∞ for test result intervals of 0–12 CU, 12–24 CU, 
24–78 CU, 78–1,050 CU, and 1,050–3,500 CU, respec-
tively, when using the PR3-ANCA and MPO-ANCA 
QuantaFlash CLIA (Inova)78.
Knowledge of test result-specific likelihood ratios 
can help clinicians and laboratory professionals to bet-
ter interpret results. Having the likelihood ratios enables 
the calculation of the post-test probability for a disease 
Figure 3 | Visual representation of the 1999 recommendations and revised 2017 recommendations. a| In the 1999 
consensus document, the recommended approach for anti-neutrophil cytoplasmic antibody (ANCA) detection was to 
screen for ANCA by indirect immunofluorescence (IIF) and to test for proteinase 3 (PR3)-ANCAs and myeloperoxidase 
(MPO)-ANCAs in IIF-positive samples; the ideal approach was to perform IIF and immunoassay on all samples. b| In the 2017 
consensus, the use of high-quality immunoassays is recommended as the preferred first screening method for ANCA 
detection in patients suspected of having the ANCA-associated vaculitides granulomatosis with polyangiitis (GPA) and 
microscopic polyangiitis (MPA). ANCA detection for non-ANCA-associated vasculitis conditions is not included in this 
consensus. *A second PR3-MPO-ANCA or IIF can be considered for negative results in patients with a high clinical suspicion 
(to increase sensitivity) or in case of low antibody levels (to increase specificity). Take antibody level into account.
a 1999 consensus
Ideal approach
b 2017 consensus
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Odds
The conversion of probability 
to odds is carried out using the 
equation odds = probability/
(1−probability). 
when the pre-test probability is known using the formula: 
post-test odds = pre-test odds × likelihood ratio78. FIGURE 4 
illustrates the post-test probability for AAV as a function 
of the pre-test probability (using the formula mentioned 
above) for different test result intervals. Such graphical 
representation is a better way to help the interpretation 
of a test result than describing the sensitivity and spec-
ificity of an assay82 and enables the post-test probability 
to be estimated from the assay test result without the 
need for a calculation. However, an estimate of the pre-
test probability is first required; the pre-test probabilities 
for AAV associated with particular clinical presentations 
can be obtained from the literature26,83,84 and have been 
previously summarized78. For instance, the pre-test prob-
ability for AAV in adult patients presenting with hae-
maturia, proteinuria and creatinine levels of 1.5–3 mg/
dL is 7%84. If ANCA testing reveals a test result with a 
likelihood ratio of 60 (for example, a test result between 
78–1,050 CU by QuantaFlash), then the post-test prob-
ability for AAV will be 82%. By contrast, the post-test 
probability of a test result with a likelihood ratio of 10.2 or 
0.1 will be, respectively, 47% and 0.7%. Such knowledge 
might add value to a specific test result and help in the 
clinical interpretation of the result.
Contraindications and considerations
The consensus recommendations proposed in this manu-
script are for detecting ANCAs in AAV, in particular GPA 
and MPA. However, ANCAs can also be found in several 
other conditions. In this section, we give an overview of 
these conditions to further help with clinical interpretation 
of ANCA test results.
ANCAs in other small-vessel vasculitides. ANCAs are 
also found in 30–38% of patients with EGPA85, a dis-
ease characterized by asthma, eosinophilia and gran-
ulomatous inflammation, and in 20–35% of patients 
with anti-glomerular basement membrane (anti-GBM) 
disease86. The majority of these ANCA-positive patients 
have MPO-ANCAs87. As the phenotypes of patients with 
EGPA are heterogeneous, EGPA was not included in this 
Consensus Statement.
ANCAs in gastrointestinal disorders. In addition to vas-
culitis, ANCAs are found in patients with gastrointestinal 
disorders such as IBD88, primary sclerosing cholangitis89 
and inflammatory liver diseases (such as autoimmune 
hepatitis, primary biliary cirrhosis and chronic viral hep-
atitis)90. These diseases are associated with a slightly aber-
rant P-ANCA pattern that is often referred to as atypical 
P-ANCA or X-ANCA88.
In gastrointestinal disorders, P-ANCA is mainly 
observed in patients with ulcerative colitis (50–67%), but 
is also seen in patients with Crohn’s disease (6–15%), and 
to a lesser extent in disease controls (<11%)88. Combining 
P-ANCA with anti-Saccharomyces cerevisiae antibody 
(ASCA) measurements might improve the clinical utility 
of this marker. ASCAs are found in 40–60% of patients 
with Crohn’s disease, 4–14% of patients with ulcerative 
colitis and <5% of controls88. The combination of an 
ASCA-positive and P-ANCA-negative test result is asso-
ciated with Crohn’s disease, whereas the combination of an 
ASCA-negative and P-ANCA-positive test result is asso-
ciated with ulcerative colitis. However, the clinical useful-
ness of ANCAs in IBD has been questioned. Given the 
limited sensitivity of ANCA detection in ulcerative colitis, 
a European evidence-based consensus on the diagnosis 
and management of ulcerative colitis concluded that rou-
tine use of ANCA detection for diagnosis and therapeutic 
decisions was not clinically justified91. 
In the past few years, studies have also reported 
that sensitive immunoassays can detect PR3-ANCAs 
in patients with ulcerative colitis50,92,93 and primary 
sclerosing cholangitis94. 
Box 1 | Recommendations for ANCA testing
The following new international recommendations should be considered for 
anti‑neutrophil cytoplasmic antibody (ANCA) detection in the small‑vessel vasculitides 
granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA):
Recommandation 1
A gating policy for requesting an ANCA test is advisable and adherence to clinical 
guidelines for ANCA testing (BOX 2) is recommended.
Recommandation 2
High‑quality antigen‑specific assays for proteinase 3 (PR3)‑ANCAs and myeloperoxidase 
(MPO)‑ANCAs should be used as the primary screening method for ANCA.
Recommandation 3
If results for both PR3‑ANCAs and MPO‑ANCAs are negative, and there is still a strong 
suspicion of small‑vessel vasculitis, then use of other immunoassays and/or indirect 
immunofluorescence (IIF), or referral to an experienced laboratory is recommended. 
Performing a second assay or IIF can also marginally increase the specificity in cases of 
low‑positive test results.
Recommandation 4
A diagnosis of ANCA‑associated vasculitis (AAV) cannot be excluded on the basis of 
negative PR3‑ANCA and MPO‑ANCA results.
Recommandation 5
A positive PR3‑ANCA and/or MPO‑ANCA result only contributes to the diagnostic 
work‑up for AAV and is not diagnostic by itself.
Recommandation 6
Taking into account antibody levels improves clinical interpretation.
Box 2 | Clinical indications for ANCA testing
In order to assure appropriate anti‑neutrophil cytoplasmic antibody (ANCA)‑test usage 
to support the diagnosis of ANCA‑associated vasculitis (AAV), ANCA should be 
requested for patients with the following clinical indications. 
• Glomerulonephritis, especially rapidly progressive glomerulonephritis
• Pulmonary haemorrhage, especially pulmonary renal syndrome
• Cutaneous vasculitis with systemic features
• Multiple lung nodules
• Chronic destructive disease of the upper airways
• Long‑standing sinusitis or otitis
• Subglottic tracheal stenoses
• Mononeuritis multiplex or other peripheral neuropathy
• Retro‑orbital mass
• Scleritis
Reproduced and adapted with permissions from Judy Savige, et al. International consensus 
statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA) (1999) 
American Journal of Clinical Pathology 111 (4); 507–513 (1999). Published online at:  
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Our consensus recommendations are applicable to 
AAV, but not to gastrointestinal disorders. As ANCAs 
can be found in gastrointestinal disorders, we advise 
differentiating between requesting ANCA tests in the 
context of AAV and in the context of gastrointestinal dis-
orders (FIG. 3). The coexistence of AAV with IBD has been 
described in some patients, but is rare95,96. In this context, 
IBD usually precedes AAV by several years96.
ANCAs in systemic inflammatory and malignant 
diseases. ANCAs have also been reported in systemic 
diseases such as rheumatoid arthritis and systemic lupus 
erythematosus (reviewed elsewhere97). A rare asso-
ciation of AAV with malignant haemopathy (mainly 
non- Hodgkin lymphoma and myelodysplasia) has 
additionally been described98.
ANCAs and infection. Evidence suggests that infections 
have a central role in the formation of ANCAs and that 
chronic infections mimic AAV99; infective endocarditis 
can mimic ANCA-associated glomerulonephritis and 
patients with infective endocarditis can develop ANCAs. 
Langlois et al.100 reported ANCAs by IIF in 12 out of 50 
patients (24%) with infective endocarditis; four patients 
had PR3-ANCAs, one patient had MPO-ANCAs and 
two patients had both PR3-ANCAs and MPO-ANCAs. 
Mahr et al.101 reported ANCA by IIF in 20 out of 109 
patients (18%) with infective endocarditis (14 patients 
were positive for C-ANCA and six were positive for 
P-ANCA); of these, three patients had C-ANCA and 
PR3-ANCAs, two patients had C-ANCA and MPO-
ANCAs, one patient had P-ANCA and MPO-ANCAs, 
one patient had just PR3-ANCAs and one patient had 
just MPO-ANCAs. Misdiagnosis of sub-acute bacterial 
endocarditis as AAV and initiation of inappropriate 
immunosuppressive therapy can have devastating con-
sequences102. Thus, infections such as infective endo-
carditis, hepatitis C infection and tuberculosis should 
be excluded before establishing a diagnosis of AAV 
and starting immunosuppressive therapy. The EUVAS 
multicentre study was performed in Europe, where 
the prevalence of infections such as malaria, leprosy 
and tuberculosis is low compared with regions such 
as India or Mexico, where positive ANCA results have 
been reported in patients with such infections103,104. 
Controversy still exists over ANCA positivity in patients 
with tuberculosis103–105.
Drug-induced AAV. Levamisole-adulterated cocaine and 
drugs such as hydralazine, propylthiouracil and mino-
cycline can cause secondary forms of AAV (reviewed 
elsewhere106,107). Vasculitis, MPO-ANCAs, PR3-ANCAs, 
human neutrophil elastase (HNE)-ANCAs and ANAs 
can all be found in patients with levamisole-adulterated 
cocaine-induced AAV107.
In a series of 30 patients with AAV associated with 
cocaine use, all patients had MPO-ANCA and 50% had 
PR3-ANCAs108; double positivity for MPO-ANCAs 
and PR3-ANCAs is a characteristic of this disease108. In 
patients with hydralazine-induced AAV, MPO-ANCAs 
can be found together with HNE-ANCAs, lactoferrin- 
ANCAs and ANAs107. In patients with propylthiouracil- 
mediated AAV, high titres of MPO-ANCAs are usually 
found107. Of note, a substantial fraction (32–41%) of 
propyl thiouracil-treated patients develop ANCAs 
(PR3-ANCAs and HNE-ANCAs) without symptoms106,109. 
In minocycline-induced AAV, P-ANCA is frequently 
found (~80% of individuals) with antibody reactivity 
against either MPO, HNE, bactericidal permeability 
increasing protein (BPI), lactoferrin or cathepsin G110–113. 
Patients are also frequently positive for ANAs.
Taken together, most patients with drug-induced 
AAV have MPO-ANCA, which can be found in combi-
nation with antibodies to other neutrophil cytoplasmic 
proteins and ANAs.
Conclusion
In the past 25 years, PR3-ANCA and MPO-ANCA 
assays have evolved from home-made assays (using 
crude extracts) that have low levels of  specificity, to 
commercially available assays with improved sensitivity 
and specificity that can be run on automated platforms. 
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Figure 4 | Post-test probability as a function of pre-test probability for different 
test result interval-specific likelihood ratios. The figure exemplifies how a graph 
can be used in practice to help in the interpretation of test results. The graph shows 
the post-test probability for anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) as a function of the pre-test probability for test results with a 
likelihood ratio of 0.1, 1, 10, 60 and ∞. In a previous study78, ANCA test result intervals 
that have a similar spread of likelihood ratios were delimited for several commercial 
assays. The equations to calculate post-test probability based on pre-test probability 
and likelihood ratio are: post-test odds = pre-test odds x likelihood ratio; 
odds = probability/(1−probability); probability = odds/(1+odds). The graph shows that 
for a patient with a pre-test probability of AAV of 7%, the post-test probability will be 
0.7%, 7%, 43%, 82% and 100% for a test result with a likelihood ratio of 0.1, 1, 10, 60 
and ∞, respectively.
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